Business Wire

RESORTTRUST

Share
The Kahala Hotel & Resort Yokohama to Open

Resorttrust, Inc. (TOKYO:4681) has announced that The Kahala Hotel & Resort Yokohama will open for business on September 23.

One of the most famous hotels in Honolulu, The Kahala Hotel & Resort, has continued to be a favorite destination of guests from around the world for more than half a century. The Kahala Hotel & Resort Yokohama represents a first step toward growing the Kahala brand worldwide.

Yokohama, at just 30 minutes by car from Haneda Airport, is very conveniently located, and is a community rich in history and with a unique culture. It is also considered to be an up and coming global city.

But there are also perfectly appropriate reasons for Yokohama to be the first place in Japan to open a Hawaiian hotel brand. In 1868, Japan’s first emigrants set off from the Osanbashi area in Yokohama to what was then the new paradise known as Hawaii. Some decades later, it was also Yokohama where the Meiji government in Japan welcomed its first state guest, King David Kalakaua from the Kingdom of Hawaii. Building on the connections between Yokohama and Hawaii, and embodying a spirit of aloha, The Kahala Hotel & Resort Yokohama will carry on the Hawaiian hospitality tradition, and looks forward to welcoming guests as ohana , the Hawaiian concept that includes both family and treasured friends.

Every effort was made to adhere to the philosophy of the Spirit of Kahala, which has carefully cultivated the Kahala brand since The Kahala was opened in Hawaii’s Kahala region 56 years ago. A new Kahala story, with a wide diversity of faces, will therefore be offered to everyone from Yokohama as well.

NOTE: The Spirit of Kahala, an offshoot of the spirit of aloha, is the source for the Kahala brand. It shows profound respect for the lives, culture, and traditions of local peoples.

Overview

Opening Date: September 23, 2020
Name: The Kahala Hotel & Resort Yokohama
Address: 1-1-3 Minato Mirai, Nishi Ward, Yokohama City, Kanagawa Prefecture
Access: Approximately eight minutes on foot from either Shintakashima or Minatomirai stations on the Minato Mirai Line, approximately six minutes by taxi from Yokohama Station on the Tokaido Line, or approximately 20 minutes from Shinyokohama Station on Tokaido Shinkansen Line.

Website: https://thekahala.jp/yokohama/
Official Facebook site: facebook.com/thekahalahotelandresortyokohama/
Official Instagram account: instagram.com/kahalaresort_yokohama

Link:

ClickThru

Social Media:

https://www.facebook.com/thekahalahotelandresortyokohama/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

L&T Technology Services Joins the MIT Media Lab to Collaborate on AI-led Innovations19.9.2025 10:30:00 CEST | Press release

With access to world-class research and breakthrough problem-solving opportunities, LTTS will explore next-gen technologies in Mobility, Sustainability and Tech L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a multi-year membership agreement with the MIT Media Lab, one of the world’s most prestigious research institutions. As a consortium Lab Member, LTTS intends to explore next-generation advancements in artificial intelligence (AI), underscoring its commitment to driving transformational innovation in Mobility, Sustainability and Tech. As part of the agreement, LTTS will engage in active discussions and information exchange with the Media Lab’s unique cross-disciplinary ecosystem that brings together researchers, innovators and industry leaders. The collaboration not only emphasizes practical AI innovation but also accelerates technology-driven advancements by linking LTTS’ expertise in AI and engineering w

SMBC Group and Jefferies Significantly Expand Their Global Strategic Alliance19.9.2025 10:00:00 CEST | Press release

Joint Venture to Combine Equities and ECM Businesses in JapanExpanding Joint Coverage of Larger SponsorsIn EMEA, Implementing Joint Origination, Underwriting and Execution of Syndicated Leveraged Finance for These ClientsSMBC to Increase Equity Ownership in Jefferies to up to 20% in the Open MarketSMBC to Provide Jefferies Approximately $2.5 Billion in New Credit Facilities to Support Jefferies and to Facilitate Collaboration Efforts Jefferies Financial Group, Inc. (NYSE: JEF) (“Jefferies”) and Sumitomo Mitsui Financial Group, Inc. (NYSE: SMFG) (“SMFG”), Sumitomo Mitsui Banking Corporation (“SMBC”), and SMBC Nikko Securities Inc. (“SMBC Nikko”) (collectively, “SMBC Group”) announced today that they are significantly expanding their Global Strategic Alliance. SMBC Group and Jefferies initially entered into a Strategic Alliance in 2021 to collaborate on future corporate and investment banking business opportunities. In 2023, the Alliance was expanded to enhance collaboration across M&A,

REJO MULTI Unveiled at InterTabac 2025, Featuring Dual-Heating and Cross-Brand Compatibility19.9.2025 10:00:00 CEST | Press release

Flexible brand options, enhanced aroma, and reduced tobacco consumption empower REJO's ambition in Europe REJO, a global heat-not-burn (HNB) pioneer, officially unveiled REJO MULTI device at InterTabac 2025 as one of the exhibition’s most anticipated products. The device introduces a dual-heating system that pairs AirFlow and Round Heating technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919713971/en/ REJO MULTI Product Launch Event “REJO MULTI represents a major step forward in HNB technology,” said Loic Li, the Global Sales Director of REJO. “Its open compatibility allows users to explore multiple brands and flavors with a single device, while our dual-heating system ensures even heating, enhanced aroma delivery, and consistent nicotine satisfaction.” “Our goal with REJO MULTI is to empower users with choice and flexibility, while providing retailers and partners with an innovative, market-ready product that

Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 18:22:00 CEST | Press release

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct

Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 17:45:00 CEST | Press release

Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global Phase III clinical trial of Omlyclo™ (CT-P39) for the treatment of chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at a satellite symposium during the 2025 European Academy of Dermatology and Venereology (EADV) Congress Celltrion highlights the strength of its expanding dermatology portfolio with positive clinical results for CT-P55, a biosimilar candidate referencing secukinumab With the launch of Omlyclo™, Celltrion underscores its commitment to advancing innovative and accessible treatments in immunology and dermatology Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye